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NOT PRECEDENTIAL 
 
UNITED STATES COURT OF APPEALS 
FOR THE THIRD CIRCUIT 
    
 
No. 18-2955 
_    
 
JOSEPH SPIZZIRRI; ABDUL RAHIMAN; KYLE KOBOLD, 
individually and on behalf of  
 all other persons similarly situated, 
Appellants 
v. 
 
ZYLA LIFE SCIENCES; ROBERT S. RADIE;  
STANLEY J. MUSIAL; JEFFREY M. DAYNO                                       
____________ 
 
Appeal from the United States District Court 
 for the Eastern District of Pennsylvania 
(District Court No. 2:17-cv-00390) 
District Judge: Honorable Michael M. Baylson  
______________ 
 
Submitted Pursuant to Third Circuit L.A.R. 34.1(a) 
September 23, 2019 
______________ 
 
Before: McKEE, AMBRO and ROTH, Circuit Judges. 
 
(Opinion filed: April 30, 2020) 
    
 
OPINION* 
 
    
 
 
 
* This disposition is not an opinion of the full court and pursuant to I.O.P. 5.7 does not 
constitute binding precedent. 
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McKEE, Circuit Judge. 
 Joseph Spizzirri appeals the district court’s grant of Egalet Corporation’s1 motion 
to dismiss. At issue in this Securities Exchange Act case is whether the district court 
erred in taking judicial notice of FDA’s Center for Drug Evaluation and Research 
memorandum and, subsequently, in granting Egalet’s motion to dismiss. 
Our review of a district court’s dismissal under Rule 12(b)(6) is de novo. We must 
accept as true all material allegations in the complaint, but “need not accept as true 
‘unsupported conclusions and unwarranted inferences.’”2 “To decide a motion to dismiss, 
courts generally consider only the allegations contained in the complaint, exhibits 
attached to the complaint and matters of public record.”3 However, a court may also 
consider matters of public record and documents integral to or explicitly relied upon in 
the complaint without converting the motion to dismiss into a motion for summary 
judgement.4 The district court’s decision to take judicial notice of certain facts is 
reviewed for abuse of discretion.5 
  It was not an abuse of discretion to take judicial notice of the CDER memo 
because, as the district court explains, the CDER memo is both a matter of public record 
 
1 After principal briefing was complete, Egalet Corporation changed its name to Zyla Life 
Sciences.  We hereby grant Appellees’ unopposed motion to amend the caption to reflect 
this change.  But to be consistent with the district court’s opinion and the parties’ 
briefing, we continue to use the company’s former name in this opinion. 
2 In re NAHC, Inc. Sec. Litig., 306 F.3d 1314, 1322-23 (3d Cir. 2002) (citation omitted). 
3 Schmidt v. Skolas, 770 F.3d 241, 249 (3d Cir. 2014).  
4 Id.  
5 In re NAHC, Inc. Sec. Litig., 306 F.3d at 1323.  
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and an authentic document “integral to or explicitly relied upon in the complaint.”6 The 
public has unqualified access to the CDER memo via the FDA’s website.7 Additionally, 
the CDER memo is integral to the complaint because Spizzirri’s claims are based on the 
document, even if it is not explicitly cited to.8 Moreover, the complaint contains exact 
language found in the CDER memo.9 “Plaintiffs cannot prevent a court from looking at 
the texts of the documents on which its claim is based by failing to attach or explicitly 
cite them.”10 
Given that the district court did not abuse its discretion in taking notice of the 
CDER memo, it follows that the district court did not err in dismissing Spizzirri’s claim 
for the failure to state a claim upon which relief could be granted. The CDER memo 
makes clear that the FDA did not grant exclusivity to Egalet’s competitor, MorphaBond, 
until after the class period ended. As the district court points out, Egalet cannot 
knowingly make false and misleading statements about the scope of exclusivity granted 
to MorphaBond, when the FDA had not yet made this very decision.11 
The district court’s carefully drafted and thorough opinion adequately addresses 
the reason for taking judicial notice of the CDER memo, and why Spizzirri cannot state a 
 
6 In re Egalet Corp. Sec. Litig., 340 F. Supp. 3d 479, 497 (E.D. Pa. 2018) (citation 
omitted). 
7 Id. at 496. 
8 Id. at 497-98. 
9 Id. at 498. 
10 In re Burlington Coat Factory Sec. Litg., 114 F.3d 1410, 1426 (3d Cir. 1997).  
11 In re Egalet Corp. Sec. Litig., 340 F. Supp at 512 (“Given that the scope of 
MorphaBond’s exclusivity remained uncertain during the class period, Defendants cannot 
be attributed with knowledge that the FDA would eventually preclude ARYMO from 
making intranasal abuse deterrence claims.”).  
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claim under the pleading standard of the PSLRA. We will therefore affirm the grant of 
the motion to dismiss Spizzirri’s claim against Egalet Corp. substantially on the reasons 
set forth by the district court in its comprehensive Memorandum.  
